Home » Newsletters » BioWorld Science

BioWorld Science

May 26, 2000

View Archived Issues

Gene linked to stress identified independently by two groups

SciClone receives patent for promising cystic fibrosis treatment

Use of verteporfin for improving xenograft transplant survival

Endovasc given green light to proceed to clinical trials with Liprostin

BMS and Ligand establish cardiovascular collaboration

Adenosine kinase inhibitor GP-515 shows good results in experimental colitis model

Esomeprazole one of the major highlights at Digestive Disease Week

Senetek acquires rights to novel compounds for topical treatment of sexual dysfunction

Abgenix establishes another XenoMouse collaboration to generate fully human antibodies

Repifermin shows positive results in phase II trial as treatment of chronic venous ulcers

Corvas and Schering-Plough further amend HCV agreement

Phase II trials of Perceptin under way at Gliatech

FDA accepts Sonus's response to EchoGen action letter

Roche files for new Tamiflu indication with FDA

PEGASYS BLA filed, clinical results reported and new study announced

Peginterferon alfa-2b monotherapy compared to standard interferon

Survival benefit seen in patients with brain tumors or metastases on RSR-13 plus cranial RT

Early phase II results justify further development of CT-2584 in patients with sarcomas

AstraZeneca reports synthesis and use of new agents for antiinflammatory therapy

Antibacterial agents with naphthyridine structure under study at SmithKline Beecham

AHP discloses new compounds for treating metabolic disorders related to insulin resistance

Selective AMPA receptor antagonists and their use presented by Schering AG

New series of glutamate receptor antagonists in development at Warner-Lambert

Pfizer synthesizes new N/OFQ receptor agonists

Dopamine D3 receptor modulators claimed by SB for use in schizophrenia

Angiomax approvable for use as anticoagulant

Protarga's new paclitaxel conjugate has favorable PK and toxicity profiles in early clinical studies

Vaccination with ras peptides as therapeutic strategy in pancreatic cancer

News from ASCO: Medarex's MDX-210 may be useful in breast cancer and ovarian cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...